Search Results
Your search for ,now matches 6673 pages
Showing 2101 - 2150Cancer in Older Adults: The History of Geriatric Oncology, Part 3
In the preceding two issues of The ASCO Post, we explored the overall history of geriatric oncology from 1980 to 2020. In this concluding part of the series, we focus on the invaluable contributions made by oncology nurses to the field. Over the past several decades, geriatric oncology has...
AACI President Knudsen to Focus 2-Year Term on Mitigating Health Disparities
Karen E. Knudsen, MBA, PhD, is the new President of the Association of American Cancer Institutes (AACI). She began her 2-year term at the close of the virtual 2020 AACI/Cancer Center Administrators Forum (CCAF) Annual Meeting. A member of AACI’s Board of Directors since 2016, Dr. Knudsen chaired ...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Chile
Chile has a population of approximately 19 million living predominantly in urban areas (87.7%), with a population density of 66 inhabitants per square mile.1 For the year 2020, approximately 12% of its population was older than 65 years.1 Socioeconomic Trends and Cancer The country has experienced ...
Expert Point of View: Andreas du Bois, MD, PhD
The invited discussant of the phase III INOVATYON trial was Andreas du Bois, MD, PhD, Chairman of the Department of Gynecology and Gynecologic Oncology at Kliniken Essen Mitte, Germany, and Chairman of the AGO Study Group. As Dr. du Bois explained, the study “dealt with an old question: Does...
Study Identifies Genetic Variants Linked to Bevacizumab-Induced Adverse Events
Researchers have found two common genetic variants that may be used to predict whether patients with cancer may have severe adverse events when treated with the anti-VEGF monoclonal antibody bevacizumab. A genome-wide association study—according to researchers, the largest such study in patients...
Potential Factors in Prognostic Discrepancies Among Tests for Recurrence Risk in Patients With Breast Cancer Receiving Endocrine Therapy
The TransATAC study reported by Buus et al in the Journal of Clinical Oncology sought to identify causes of discrepancies among tests for determining the risk of breast cancer recurrence in patients with estrogen receptor–positive, HER2-negative disease receiving endocrine therapy. The...
An Integrated Framework for Improving Outcomes in Pancreatic Cancer
Drawing on several lines of ongoing research, David A. Tuveson, MD, PhD, has created a theoretical framework to consider while developing clinical trials in pancreatic cancer. In his keynote lecture at the 2020 American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer, ...
Systemic Therapy in the First- and Second-Line Treatment of Advanced Hepatocellular Carcinoma: Review and Meta-analysis
In a systematic review and network meta-analysis of 14 trials reported in JAMA Oncology, Sonbol et al found that atezolizumab plus bevacizumab outperformed other regimens in the first-line treatment of advanced hepatocellular carcinoma and identified preferred treatments in refractory disease. As...
Pretreatment ctDNA May Help Predict Outcomes With First-Line—but Not Second-Line—Immunotherapy for Patients With Melanoma
A study by Marsavela et al published in Clinical Cancer Research evaluating the predictive value of pretreatment circulating tumor DNA (ctDNA) to inform therapeutic outcomes in patients with advanced-stage melanoma relative to type and line of treatment has found that baseline levels of ctDNA...
Fluciclovine PET Imaging vs Conventional Imaging in Prostate Cancer
The addition of the radiotracer fluciclovine to positron-emission tomography (PET) imaging for treatment planning led to superior failure-free survival compared with conventional imaging in men with prostate cancer who had undergone radical prostatectomy and were experiencing biologic recurrence of ...
Becoming Acquainted With Cancer
Editor’s Note: The ASCO Post learned of the death of Patrick Beauregard due to colorectal cancer on September 6, 2020. Just weeks after my wedding in late summer of 2017, I had a sudden bout of abdominal pain so severe that it sent me to the emergency room. I was just 29 years old and in great...
Remembering Patrick H. Beauregard: ‘Selfless in His Efforts to Raise Awareness’ of Colorectal Cancer in Young Adults
The editors of The ASCO Post are sad to report the death of Patrick H. Beauregard on September 6, 2020. The cause was colorectal cancer. Diagnosed with stage IV disease in 2017 at the age of 29, Mr. Beauregard dedicated the last 3 years of his life to raising awareness of colorectal cancer in...
Emily Whitehead, Early Recipient of CAR T-Cell Therapy for ALL, Celebrates 8 Years Cancer-Free
Among the success stories in the treatment of acute lymphoblastic leukemia (ALL) in children and young adults is the development of chimeric antigen receptor (CAR) T-cell therapy. The field of cellular immunotherapy was still in its infancy in 2012 when Emily Whitehead, then 7, became the first...
Personal Testimonial: CAR-modified T Cells in Adults
Twelve adults with chronic lymphocytic leukemia (CLL) have been treated with CD19-targeted chimeric antigen receptor (CAR) T-cell therapy at the University of Pennsylvania in Philadelphia by Carl June, MD, Richard W. Vague Professor in Immunotherapy, and colleagues. These were all end-stage...
Preliminary Progress with Genetically Engineered T Cells in Treating Childhood ALL
Two small phase I studies at separate centers demonstrated encouraging results in the treatment of children with acute lymphoblastic leukemia (ALL) using reinfused autologous genetically engineered T cells. Results of both studies were presented at the Annual Meeting of the American Association for ...
New ASCO-SEP Edition Available: Expands Reach to Global Oncology Community
The seventh edition of the ASCO Self-Evaluation Program® (ASCO-SEP®) is now available online, expanding its reach to physicians and advanced practitioners. The latest edition features new content that addresses oncologic care in a global setting. The new edition of ASCO-SEP includes 22 chapters of...
The Gut, Our Choices, and Gynecologic Cancers: Investigating an Unlikely Trio
Disturbance of the gut microbial metabolism is thought to be the root cause of human diseases. Bacteria, viruses, and fungi affect their human hosts in numerous ways. There is evidence to support the theory that microbes, through their genetic makeup, gene products, and metabolites, play a role in...
Expert Point of View: Bartosz Chmielowski, MD, PhD
The invited discussant of LEAP-004, Bartosz Chmielowski, MD, PhD, Associate Clinical Professor at the University of California Los Angeles Jonsson Comprehensive Cancer Center, commented: “The response rate of 21% was quite impressive for this patient population. Patients previously treated with an...
Expert Point of View: Salah-Eddin Al-Batran, MD
Salah-Eddin Al-Batran, MD, Director of the Institute of Clinical Cancer Research and Director of GI Oncology at Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, commented on KEYNOTE-590 at a press briefing. Dr. Al-Batran noted that the prognosis for advanced esophageal cancer is...
Panel With Diverse Perspectives Explores Strategies to Reduce Costs for Cancer Care
“Imagine that it’s 5 years from now, and we are in a situation where the cost of cancer care has flattened, and costs are even going down,” said Clifford Goodman, PhD, a Senior Vice President at the Lewin Group, turning to a panel of oncology and policy experts at his side. “What policies got us...
Daughter of an Orthopedic Surgeon, Abigail T. Berman, MD, Finds Radiation Oncology Intriguing
Radiation oncologist Abigail T. Berman, MD, was born and reared in Philadelphia, the daughter of an orthopedic surgeon whose passion for his work was an early influence on her decision to pursue a career in medicine. “My father absolutely adored his job and worked very hard, which inspired me to...
Cancer in Older Adults: The History of Geriatric Oncology, Part 2: 1990–2020
In part 1 of this three-part article, which was published in the October 10, 2020, issue of The ASCO Post, we chronicled the progress made in geriatric oncology up to the decade of the 1990s, which saw an explosion of research activity in the study of aging and cancer. In part 2, we review the...
James K. McCloskey II, MD, Named Division Chief of the Division of Leukemia at John Theurer Cancer Center
James K. McCloskey II, MD, was named Division Chief of the Division of Leukemia at Hackensack Meridian John Theurer Cancer Center (JTCC), part of Hackensack University Medical Center. Dr. McCloskey previously served as Interim Chief for the Division of Leukemia and will continue in his role as...
Expert Point of View: Chiara Cremolini, MD, PhD
The KEYNOTE-177 invited discussant, Chiara Cremolini, MD, PhD, of the University of Pisa, Italy, welcomed the patient-reported outcomes of the study, noting that such data are frequently missing. “Unfortunately, quality of life is an often-disregarded issue in colorectal cancer clinical trials,”...
First-Line Pembrolizumab in Metastatic Colorectal Cancer: Quality of Life Also Improved
In KEYNOTE-177, the anti–PD-L1 antibody pembrolizumab reduced the risk of disease progression by 40% vs chemotherapy in a targeted subset of previously untreated patients with metastatic colorectal cancer. Now, in terms of health-related quality of life, pembrolizumab is also the clear favorite,...
Thinking Out of the Box to Advance the Management of Chronic Graft-vs-Host Disease
Over the past decade, the field of allogeneic hematopoietic cell transplantation has made great strides, evolving into a curative procedure for blood cancers that once were almost always fatal. However, chronic graft-vs-host disease, whose biologic etiology remains unclear, continues to be the...
Florida Surgeon Steven D. Wexner, MD, FACS, Elected Vice-Chair of Board of Regents of American College of Surgeons
Steven D. Wexner, MD, PhD (Hon), FACS, FRCS (Eng), FRCS (Ed), FRCSI (Hon), Hon FRCS (Glasg), was recently elected Vice-Chair of the Board of Regents of the American College of Surgeons (ACS) during the College’s virtual Clinical Congress 2020, held October 3–7. Dr. Wexner is Chair of the...
2020 Nobel Prize in Physiology or Medicine Awarded to Team Who Discovered Hepatitis C Virus
This year’s Nobel Prize in Physiology or Medicine was awarded to three scientists who have made a decisive contribution to the treatment of blood-borne hepatitis, a major global health problem that causes cirrhosis and liver cancer in people around the world. Harvey J. Alter, MD; Michael Houghton,...
Early-Phase Study Reports Progress in Targeting KRAS-Mutated Tumors With Sotorasib
Although KRAS is one of the most frequently mutated oncogenes in human cancers, an almost 4-decade long search for drugs that hit this target has been elusive—until now. Sotorasib (formerly called AMG-510), a small-molecule inhibitor of the KRAS G12C mutation, demonstrated clinical activity and...
Expert Point of View: Roy S. Herbst, MD, PhD, FACP, FASCO
Invited discussant of the EMPOWER-Lung 1 trial, Roy S. Herbst, MD, PhD, FACP, FASCO, Chief, Medical Oncology, Yale Cancer Center, New Haven, Connecticut, pointed out the tremendous progress that has been made since 2000 in treating NSCLC. “In 2000, median survival for advanced NSCLC was 7.9...
Expert Point of View: Sjoukje Oosting, MD, PhD
Invited discussant of the xevinapant study, Sjoukje Oosting, MD, PhD, of the University Medical Center Groningen, the Netherlands, commented: “There is finally hope on the horizon that we can increase the cure rate of our patients with head and neck cancer, if these data are confirmed in a phase...
Expert Point of View: Fatima Cardoso, MD
The encouraging results of the phase III ASCENT trial suggest that sacituzumab govitecan has clearly earned a place in the treatment algorithm for advanced triple-negative breast cancer, said the study’s invited discussant, Fatima Cardoso, MD, Director of the Breast Unit at the Champalimaud...
Sacituzumab Govitecan Yields Survival Benefit as Third-Line Treatment in Triple-Negative Breast Cancer: ASCENT Trial
Based on results from a phase I/II clinical trial, the antibody drug conjugate sacituzumab govitecan was recently granted accelerated approval in the treatment of patients with advanced triple-negative breast cancer, contingent on a larger study confirming its benefit. The confirmatory phase III...
COVID-19, Cancer, and the Older Adult
An inspiring case series of fit patients aged 98 and older who recovered from hospitalization for COVID-19, published by Huang et al, reminds us that older age may not be a barrier to recovery.1 On behalf of the Cancer and Aging Research Group, we do not support “ageism” in the care of older...
Should Body Mass Index Guide the Choice of Chemotherapy in Patients With Breast Cancer?
The rate of obesity is rising dramatically in the United States and Europe, with more than 60% of women in the United States1,2 and 50% of women in Europe3 classified as overweight or obese based on their body mass index (BMI). Obesity is associated with an increased risk of hormone...
Small Case Study Explores Novel Approach to Neoadjuvant Therapy for Skin Cancer
Skin cancers are the most common malignancy in the United States and worldwide. Between 1994 and 2014, the diagnosis and treatment of melanoma and nonmelanoma skin cancers in the United States increased by 77%.1 The cost of treating melanoma and nonmelanoma skin cancers to the health-care system...
Advanced Practitioner Leadership in Times of Crisis
In 2020, health-care providers from all disciplines are facing challenges never before encountered in the modern era of medicine. Advanced practitioners (APs) are playing critical roles in developing protocols, managing health-care teams, and delivering hands-on patient care. JADPRO Live, the...
ASCO Approves First Joint MSTS/ASTRO/ASCO Guideline on Treatment of Metastatic Carcinoma and Myeloma of the Femur
On June 20, 2020, ASCO approved the first joint Musculoskeletal Tumor Society (MSTS)/American Society for Radiation Oncology (ASTRO)/ASCO guideline on the care of patients with metastatic carcinoma and myeloma of the femur.1 Guideline recommendations were based on a systematic review of clinical...
Expert Point of View: Rodabe N. Amaria, MD
The value of adjuvant therapy for patients with resected stage III or IV melanoma—in the form of pembrolizumab and nivolumab—continues to be observed after approximately 4 years from the start of therapy, according to Rodabe N. Amaria, MD, Associate Professor of Melanoma Medical Oncology at The...
Long-Term Benefit of Adjuvant Immunotherapy Sustained in Stage III or IV Melanoma
The benefit of anti–PD-1 antibodies in the adjuvant treatment of patients with stage III or stage IV melanoma continues to be observed at around 4 years for both pembrolizumab and nivolumab, according to updates of pivotal trials presented at the European Society for Medical Oncology (ESMO) Virtual ...
Limited English-Language Proficiency May Affect Frequency of Screening Mammograms
Limited English-language proficiency may be a risk factor for receiving screening mammograms less often, according to new study results using national data. These findings, concerning women age 40 and older living in the United States, were presented at the American College of Surgeons Clinical...
New Study Offers a Global Review of the Impact of COVID-19 on Cancer Treatment and Research
A recent review of scientific literature showed that the COVID-19 pandemic has impacted virtually every aspect of cancer care and research—from introducing new risks for patients to disrupting the delivery of treatment and the continuity of research. The report, published by Ziad Bakouny, MD, and...
Research Into 'Cold' Tumors Heating Up in Pancreatic Cancer
Immunotherapy has changed the treatment paradigm for cancer, inducing durable responses in a subset of patients with previously refractory disease. However, current approaches are successful in only approximately 20% of cancers (so-called hot tumors). For the nearly 80% of cancers that are “cold”...
Can Routine Scans Help Predict Which Patients With Breast Cancer May Be at Risk for Heart Disease?
Automated analysis of the routine scans of patients with breast cancer may help to predict which women have a greater risk of developing cardiovascular disease, according to research presented by Gal et al at the 12th European Breast Cancer Conference (Abstract 7). Women who have been treated for...
Oral Cancer Pain May Predict Likelihood of Metastasis
Oral cancer may be more likely to spread in patients experiencing high levels of pain, according to a team of researchers who found genetic and cellular clues as to why metastatic oral cancers are so painful. These findings were published by Bhattacharya et al in Scientific Reports. Researchers...
Making Strides in the Management of Pancreatic Cancer
The Special Conference on Pancreatic Cancer, sponsored by the American Association for Cancer Research (AACR) and held virtually this year, showcased cutting-edge discoveries and promising advances in the understanding and treatment of pancreatic cancer, reported by some of the world’s foremost...
Bolder, More Aggressive Steps Needed to Achieve Cancer Care Equity
ASCO called for new actions to reduce disparities in cancer outcomes affecting racial and ethnic minorities, rural populations, sexual and gender minorities, people without insurance, and other disadvantaged populations. In a policy statement published in the Journal of Clinical Oncology (JCO),...
Art of Oncology: On the Page and in a Podcast, Personal Reflections From Oncologists Are a Fitting Companion Amid the COVID-19 Pandemic
The well-loved Art of Oncology section of the Journal of Clinical Oncology (JCO) and its pioneering podcast are both resonating as never before, as cancer specialists are prompted into deeper reflections about the poignant moments that give life meaning by the COVID-19 pandemic. JCO’s Art of...
Dana-Farber Opens Clinical Trial to Evaluate Simple Blood Test for Many Types of Cancer
Recent advances such as immune, cellular, and targeted therapies have provided new and effective means to treat a variety of cancers. Despite this considerable progress, cancer caught in its earliest stages remains the most curable. That is why Dana-Farber Cancer Institute is opening a new clinical ...
Surgical Oncologist Diane M. Simeone, MD, Strives to Improve Outcomes for Patients With Pancreatic Cancer
Despite decades of research and clinical advances, the diagnosis and treatment of pancreatic cancer remain formidable challenges. Recently, enormous efforts have been made to develop new methods for the early diagnosis and treatment of pancreatic cancer, such as those led by Diane M. Simeone, MD, a ...
